and Human Services (HHS) procedures for the detection of heroin abuse by testing urine utilize an initial opiate (codeine/morphine) immunoassay (IA) screen followed by gas chromatography-mass spectrometry (GC-MS) confirmation of 6-acetylmorphine (6-AM), if the morphine concentration is above established cutoff. An alternative to the current opiates screen for heroin abuse is the direct IA for the metabolite of heroin, 6-acetylmorphine. In this regard, the performance of the Microgenics CEDIA heroin metabolite (6-AM) screening reagent was assessed. This evaluation was conducted on the P module of a Hitachi Modular automated IA analyzer calibrated using 6-AM at 10 ng/mL. Reproducibility, l i n e a r i t y, accuracy, sensitivity, and interferences associated with use of the 6-AM IA reagent were evaluated. The IA reagent precision (percent coefficient of variation (%CV)) around each of seven standards was less than 0.63%, with a linearity (r 2 ) value of 0.9951. A total of 37,713 active duty service members' urine samples were analyzed simultaneously using the CEDIA heroin metabolite (6-AM) reagent and the Roche Abuscreen ONLINE opiate reagent to evaluate both the prevalence rate of 6-AM in the demographic group and the sensitivity and specificity of the reagents for the detection of heroin use. Of the 37,713 samples tested using the CEDIA heroin metabolite (6-AM) reagent, three samples screened positive at the DoD and HHS cutoff of 10 ng/mL. One of the three samples confirmed positive for 6-AM by GC-MS above the cutoff of 10 ng/mL, the two remaining samples confirmed negative for 6-AM at a GC-MS limit of detection (LOD) of 2.1 ng/mL. In contrast, the Roche Abuscreen ONLINE opiate IA produced 74 opiate-positive results for codeine/morphine, with 6 of the 74 specimens confirming positive for morphine above the DoD cutoff concentration of 4000 ng/mL (8% DoD morphine confirmation rate), only one of the 74 opiate-positive screen specimens confirmed positive for 6-AM above the 10 ng/mL GC-MS cutoff concentration. As a further check of the sensitivity and specificity of the Microgenics 6-AM IA reagent, human urine samples (n = 87) known to contain 6-AM by GC-MS, were re-analyzed using both IA reagents. All 87 of the samples screened positive using the CEDIA heroin metabolite (6-AM) assay. However, using the Roche ONLINE opiate reagent, 12 of the known 6-AM positives screened negative at the DoD and HHS screening cutoff of 2000 ng/mL (morphine). Of the remaining 75 samples that screened positive by the ONLINE opiate reagent, five of the samples did not contain morphine above the DoD GC-MS cutoff concentration of 4000 ng/mL and would not have required 6-AM analysis. However, under the HHS GC-MS morphine cutoff concentration of 2000 ng/mL all 75 samples would have required 6-AM analysis. Furthermore, using the current DoD opiate screen, 17 out of 87 samples known to contain 6-AM would have gone undetected (19.5% false-negative rate); additionally, even under the more stringent HHS opiate screening standards 12 out of the 87 samples known to contain 6-AM would also have gone undetected (13.8% false-negative rate). The Microgenics CEDIA heroin metabolite (6-AM) reagent assay appears well adapted for the rapid and specific detection of heroin abuse as an alternative f o r, or an adjunct test to, the current opiates (codeine/morphine) IA screening procedure.
Introduction
H e roin was first synthesized by acetylation of morphine in 1874, and made available as a pharmaceutical preparation in 1898 (1) . Heroin is obtained from the resin of the seedpod f rom the plant, Papaver somniferu m. Disturbingly, while the s t reet cost of heroin has decreased over the past several years, illicit production and purity has increased. In vivo, heroin is rapidly and predominately metabolized by deacetylation to 6-acetylmorphine (6-AM), and subsequently to morphine (2) . The urinary elimination half-life of heroin and 6-AM is app roximately 2-6 min and 30 min, respectively (3) . The rapid metabolism of heroin and to a lesser extent, 6-AM, provides a urine detection window for these compounds of appro x i m a t e l y 3-18 h. The presence of 6-AM in urine is used to substantiate h e roin use, as 6-AM is not produced metabolically in humans f rom either codeine or morphine (4) .
In 1983, the Department of Defense (DoD) implemented a gas c h romatographic-mass spectrometric (GC-MS) confirm a t i o n d rug-testing program to detect and deter the use of contro l l e d substances by military personnel (5) . To detect improper use of opiate containing medication or heroin, urine samples were subjected to an initial immunoassay (IA) screen and a confirmation assay utilizing GC-MS. The presence of codeine and morphine at concentrations equal to or above 300 ng/mL by GC-MS implied possible use of prescription medications or the illicit use of morphine and/or heroin. In 1987, however, S t ruempler (6) re p o rted that food products containing poppy seeds were capable of causing a positive result for morphine at the DoD cutoff concentration of 300 ng/mL. Several subsequent studies supported this finding (7, 8) . As a result, DoD inc reased both the screening cutoffs for codeine and morphine to 2000 ng/mL and confirmation cutoffs to 2000 and 4000 ng/mL, re s p e c t i v e l y. In 1986, to diff e rentiate heroin use from medicinal opiate use, DoD implemented 6-AM testing as an adjunct to morphine GC-MS analysis whenever the morphine concentration was greater than 4000 ng/mL.
H i s t o r i c a l l y, the majority of codeine/morphine positive (6-AM negative) results re p o rted in the military are associated with use of medication from a valid prescription. Whereas the circ u mstances pertaining to opiate use in these cases ultimately vindicate the service member, a significant amount of time and money can be expended in determining this medical re l a t i o nship. Depending on the duty assignment, the military member is often reassigned or relieved from his/her primary duties pending review of his/her medical re c o rd by a military medical review officer (MRO). Thus, the re p o rting of a military member who is subsequently shown to have a valid prescription as opiate positive is costly, personally and administratively, for both the MRO and the sample donor.
The ability to screen specifically for the 6-AM metabolite, rather than codeine/morphine, could be of value by focusing testing on illicit drug use and vice prescription drug use or abuse. The CEDIA heroin metabolite (6-AM) IA was evaluated to d e t e rmi ne if this reagent provided superior analytical perf o rmance for the detection of the heroin metabolite, as well as its e ffectiveness and suitability as an alternative or adjunct to the c u rrent opiates (codeine/morphine) based IA scre e n .
Materials and Methods

Immunoassay
Immunoassay screening for 6-AM was perf o rmed on the P module of a Roche/Hitachi Modular automated scre e n i n g analyzer (Indianapolis, IN) using the Microgenics (Fre m o n t , CA) CEDIA heroin metabolite (6-AM) assay. The generalized opiate IA screen was perf o rmed using the Abuscreen ONLINE opiate kit from Roche Diagnostics Inc. (Indianapolis, IN). The Hitachi P module was calibrated daily prior to running samples using a single-point calibration, per manufacturer specifications, at 10 ng/mL and 2000 ng/mL for 6-AM and morphine, res p e c t i v e l y. The resulting absorbance value for the calibrator was normalized to 100 arbitrary units.
All calibrators, controls, and standards were pre p a red by dilution of a 100 µg/mL 6-AM standard or 1 mg/mL morphine s t a n d a rd purchased from Cerilliant (Austin, TX) with cert i f i e d d ru g -f ree urine purchased from Bio-Rad Laboratories (Irv i n e , CA). A low 6-AM IA control was pre p a red at 7.5 ng/mL and a high IA control was pre p a red at 12.5 ng/mL. Certified dru g f ree urine spiked with 6-AM at 0, 5, 7.5, 10, 12.5, 15, and 20 ng/mL was used to determine the linearity, precision, and accuracy of the assay. All IA reagents, controls, and calibrators w e re utilized in accordance with the manufacture r' s instru c t i o n for the analysis of urine samples.
Extraction
Solid-phase extraction (SPE) columns (ZCDAU020) used in the analysis were purchased from United Chemical Te c h n o l ogies, Inc. (Bristol, PA). The columns were conditioned with 3 mL of methanol followed by 3 mL of deionized water and lastly with 1 mL of 0.1M phosphate buffer (pH 6). Urine samples w e re added to the SPE columns and allowed to flow by gravity. The columns were washed sequentially with 2 mL deionized w a t e r, 2 mL acetate buffer (pH 4.5), and 3 mL of methanol. Columns were aspirated to dryness by vacuum, for 5 min. Samples were eluted into 16 × 100-mm test tubes using 3 mL of methylene chloride/isopropanol/ammonium hydro x i d e (78:20:2); all solvents were high-perf o rmance liquid chromatography (HPLC) grade. Samples were evaporated to dry n e s s under nitrogen using the Tu r b o Vap LV, (Zymark Incorporated, Hopkinton, MA) at 55ºC. Samples were derivatized using 50 mL each of ethyl acetate (Fisher Scientific, Fair Lawn, NJ) and p e n t a f l u o ro p ropionic anhydride (PFPA) (Aldrich, Milwaukee, WI). Sample tubes were capped, vortex mixed, and incubated at room temperature for 60 min. The extracts were dried down under nitrogen using the Tu r b o Vap LV at 55ºC, reconstituted in 50 mL ethyl acetate, transferred to properly labeled GC-MS vials, and capped. Internal standard was 6-acetylmorphine-d 3 a t 10 ng/mL and purchased from Cerilliant (Round Rock, TX).
6-AM GC-MS analysis
GC-MS analysis was perf o rmed on samples screening positive for 6-AM using an Agilent (Palo Alto, CA) 6890 GC coupled to a 5973 mass selective detector (MSD). A G2614A autosampler c o n t rolled by Agilent ChemStation software (version G17101CA) facilitated the GC-MS vial processing. A GC fusedsilica capillary column (20 m × 0.18 mm × 0.18 mm) purchased from J&W (Palo Alto, CA) was used for chro m a t o g r a p h i c separation. The carrier gas was helium, at a constant flow of 1 mL/min. The initial GC oven temperature of 165°C was ramped to 265°C at a rate of 10°C/min then from 265°C to 300°C at 40°C/min with a final hold time of 2 min. The MSD was operated in selected ion monitoring (SIM) acquisition mode. The qualifying ions for the identification of 6-AM were m / z 361 and m/z 473; ion m / z 364 was used for the intern a l s t a n d a rd 6-AM-d 3 . The quantitation ions were m / z 414 and m / z 417 for 6-AM and 6-AM-d 3 , re s p e c t i v e l y. The limit of q u a n t i t ation (LOQ) was the lowest concentration of dru g , w h e re all ion ratios are acceptable, and the observed concentration is within ± 20% of the theoretical concentration. The limit of detection (LOD) was the lowest concentration of d rug where all ion ratios are acceptable, though the observ e d quantitation may be outside of ± 20% of the theoretical. The LOQ and LOD for the assay was 2.1 ng/mL. The upper limit of linearity, the highest concentration that produced acceptable ion ratios and a concentration within ± 20% of the theo retical, was 100 ng/mL.
Results and Discussion
Analytical precision, accuracy, and linearity of the CEDIA h e roin metabolite (6-AM) reagent were evaluated using 10 replicates each of 6-AM standards pre p a red at 0, 5, 7.5, 10, 12.5, 15, and 20 ng/mL. The mean (X), standard deviation (SD), and percent coefficient of variation (%CV), were calculated using absorbance measurements (Table I ). The assay was linear f rom 0 to 20 ng/mL exhibiting a correlation coefficient of 0.9951 (Figure 1) . Each of the linearity standards produced a %CV of less than 0.63%.
C a rry o v e r, the unintentional contamination of one specimen by another, was assessed by assaying 6-AM standards ranging in concentration from 10 to 10,000 ng/mL, water blanks placed between each standard are included to identify contamination.
No carryover of 6-AM to the water blanks was observed at any of the concentrations used.
Reagent specificity was evaluated using multi-constituent and single drug standards containing 67 prescription and "over the counter" drugs, their metabolites and illicit drugs. These d rugs and metabolites are in their "free" form and are not conjugates formed during metabolism. All non-opiate related compounds analyzed yielded negative results at concentrations ranging from 5000 to 2,000,000 ng/mL, expressed as concentrations from 0.005 to 2 mg/mL (Table II) . A panel of s t ructurally related opiates was also analyzed for potential c ro s s -re a c t i v i t y. In contrast to the structurally unrelated compounds, some of the related compounds yielded positive screening results (Table III) . For example, free morphine at a concentration of 12,500 ng/mL (expressed as 0.0125 mg/mL in Table III ) produced a positive IA screening result using the 6-AM reagent. The significance of this is limited, however, because only 10% of a morphine dose is excreted as fre e morphine (3). Whereas the low cross-reactivity of the CEDIA heroin metabolite (6-AM) reagent may reduce unwanted positive screens involving morphine, it may unintentionally allow morphine abuse to go undetected. This issue can be addre s s e d by randomly testing a percentage (e.g., 20-40%) of all samples submitted for drug analysis using an opiate (codeine/morphine) IA reagent. Because all military labs currently pulse test for opiates, continuing to pulse test (i.e., test a defined number or percentage of, but not all, donor samples) for opiates, using the current opiate reagent, would still provide a re asonable measure of deterrence if morphine or codeine abuse were suspected. A total of 37,713 human urine service member samples, collected randomly under forensic conditions, were analyzed to evaluate the perf o rmance of the CEDIA heroin metabolite (6-AM) reagent. Each analytical batch was bracketed by a "High" c o n t rol containing 6-AM at 125% of the cutoff and a "Low" c o n t rol pre p a red at 75% of the cutoff. Between run pre c i s i o n and accuracy was evaluated by calculating the mean, SD, and %CV of these controls. The assay exhibited control perf o rm a n c e
, and 9.9% respectively for the low control. A negative blind contro l was included with each analytical batch. There were no contro l f a i l u re s .
Of the 37,713 service member samples, 3 samples scre e n e d positive for 6-AM using a cutoff of 10 ng/mL (Table IV) . Howe v e r, only one of the three samples confirmed positive for 6-AM by GC-MS at the DoD and HHS cutoff concentration of 10 ng/mL. The positive sample contained 6-AM at a concentration of 172 ng/mL. Additional analysis by the Armed Forc e s Institute of Pathology (AFIP) and Microgenics into the cause of the two false-positive screening results was inconclusive. The 6-AM confirmation rate for this method was 33%. By comparison, screening results for the same sample set, using the Roche A b u s c reen ONLINE opiate kit (with a morphine cutoff of 2000 ng/mL), yielded 74 presumptive positive samples (Table IV) . C o n f i rmation for morphine and codeine was perf o rmed using GC-MS at the DoD cutoff concentrations of 4000 and 2000 ng/mL, re s p e c t i v e l y. Additionally, reflex GC-MS analysis for 6-AM was perf o rmed on all samples with morphine concentration g reater than or equal to 4000 ng/mL. Six of the samples met the DoD re q u i rements mandating further 6-AM confirmation analysis. Of these, one sample confirmed positive (Table IV) . The resulting 6-AM confirmation rate, after the two steps of an initial s c reen and subsequent GC-MS morphine analysis, was 17%. Although both screening pro c e d u res properly identified the sample that ultimately confirmed positive for 6-AM, the CEDIA h e roin metabolite (6-AM) reagent identified only three samples requiring GC-MS confirmation. The Abuscreen ONLINE opiate reagent on the other hand, identified 74 samples re q u i r i n g GC-MS opiates confirmation analysis. Import a n t l y, 6 of the 74 samples identified by the ONLINE opiate reagent re q u i red further GC-MS 6-AM analysis to identify the one positive 6-AM sample (Table IV) .
The Office of the Chief Medical Examiner (OCME), Baltim o re, MD, provided a total of 87 human urine samples pre v iously confirmed positive for 6-AM. The samples were analyzed using the CEDIA heroin metabolite (6-AM) reagent to detect 6-AM-positive samples and the Abuscreen ONLINE opiate reagent to detect morphine-positive samples that would req u i re further 6-AM analysis. The 6-AM and morphine concentrations for these samples ranged from 22 to 7113 ng/mL and 173 to 550,880 ng/mL, re s p e c t i v e l y. All of the samples produced a positive screening result using the CEDIA hero i n metabolite (6-AM) reagent. In contrast, 12 of the samples produced a negative result (morphine cutoff concentration of 2000 ng/mL) using the Roche Abuscreen ONLINE opiate re a g e n t . Five additional samples positive at initial screen using the Roche Abuscreen ONLINE reagent, confirmed below the DoD GC-MS morphine cutoff of 4000 ng/mL. These specimens would not have been processed for 6-AM analysis and there f o re would have gone undetected. With the more stringent HHS guidelines, all 75 samples screening above the opiate IA 2000 ng/mL cutoff would have undergone 6-AM conformational analysis. Intere s t i n g l y, out of the 87 samples detected by the CEDIA h e roin metabolite (6-AM) reagent, 19.5% of the 6-AM positive samples would not have been detected using the current DoD * An ONLINE positive screen requires a morphine concentration of greater than 4000 ng/mL as determined by GC-MS to proceed to 6-AM confirmation analysis.
492
guidelines; 13.8% of the 6-AM positive samples would not have been detected using the current HHS guidelines.
